HC Wainwright & Co. Downgrades Esperion Therapeutics to Neutral, Announces $3.16 Price Target

Benzinga Newsdesk www.benzinga.com Negative 88.8%

Neg 88.8% Neu 0% Pos 0%

HC Wainwright & Co. analyst Joseph Pantginis downgrades Esperion Therapeutics (NASDAQ:ESPR) from Buy to Neutral and announces $3.16 price target.